193 results about "Non steroidal" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

The invention discloses a long-acting analgesic compound as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing a mixed solution containing a polymer, a local anesthetic, a non-steroidal anti-inflammatory drug and a solvent into drug-loaded microspheres through an electrostatic spraying technology; the preparation method comprises the following steps: dissolving poloxamer and a natural polymer material in water to obtain a hydrogel solution; and uniformly mixing the drug-loaded microspheres and a hydrogel solution to prepare the long-acting analgesic compound. The long-acting analgesic compound comprises drug-loaded microspheres and hydrogel, the long-acting analgesic compound and the hydrogel are both of a three-dimensional porous network structure, the drug-loaded microspheres are evenly dispersed in the hydrogel, and the drug-loaded microspheres are of a solid spherical structure. The advantages of electrostatic spraying microspheres and hydrogel are combined, the preparation method is mild in condition and simple in process, and the preparation process is non-toxic and harmless; the long-acting analgesic compound has the advantages of thermosensitivity, injectability, high drug loading rate and the like, and can be effectively applied to preparation of analgesic products.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a pH response hydrogel microneedle, which comprises a microneedle substrate, microneedle tips are arranged on the microneedle substrate, the height of the microneedle tips is 100-1600 microns, the diameter of the tip ends of the microneedle tips is 5-15 microns, and the density of the microneedle tips is 200-1000 pieces per square centimeter. The preparation method comprises the following steps: preparing a hyaluronic acid solution for the microneedle substrate, preparing a methacrylated chondroitin sulfate solution for the microneedle tip, preparing methacrylated orthoester, preparing orthoester, preparing a non-steroidal anti-inflammatory drug solution, preparing a microneedle tip solution, preparing the microneedle and demolding the microneedle to prepare the complete soluble microneedle patch. The invention has the advantages of high drug efficiency, high efficiency in dissolving fat / water drugs, and long-acting slow release.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a green synthesis process of non-steroidal loxoprofen sodium, and relates to the field of loxoprofen sodium synthesis. A water / organic two-phase free radical bromination and functionalized Pd-Ru / NH2-ZIF-8 catalysis one-step hydrogenation degreasing-tert-butyl ester removal path is adopted. The catalyst is modified by a thiol ligand and cooperates with a chiral inducer to construct a Pd-Ru bimetallic active site, so that the product purity and the product yield are effectively improved, and the catalyst can be repeatedly used. The method is environment-friendly and efficient in process and suitable for industrial application.

The application provides a method for analyzing the synergistic mechanism of hepatotoxicity and nephrotoxicity of non-steroidal anti-inflammatory drugs. The method comprises the following steps: preliminary toxicity prediction of NSAIDs and collection of toxicity target points, collection of liver and kidney disease target points, then cross and screening of the target points to obtain core target points and common core target points of NSAIDs induced liver and kidney diseases, and then constructing a protein interaction network of the common core target points; enrichment analysis of the common core target points to obtain the common action pathway of NSAIDs induced liver and kidney diseases; finally, further screening of the common core target points to obtain the key target points of NSAIDs induced liver and kidney diseases, and verification by using molecular docking technology. Compared with the traditional method, the advantages of the method are: first, the method does not depend on large-scale patient clinical data and a large number of animal or cell experiments, avoiding the ethical controversy in animal experiments and human experiments; second, the method can identify the potential cross-pathway and synergistic toxicity mechanism when a compound triggers multiple diseases, which is helpful for more comprehensive evaluation of the toxicity risk of NSAIDs.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

A composition for combating metabolic diseases and its use (or method). The pharmaceutical composition comprises a therapeutic agent A or a pharmaceutically acceptable salt thereof; a therapeutic agent B or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, wherein the therapeutic agent A is a non-steroidal anti-inflammatory drug and the therapeutic agent B is a fatty acid oxidation inhibitor. The pharmaceutical composition can effectively treat or prevent metabolic syndrome diseases caused by obesity, non-alcoholic fatty liver disease, polycystic ovary syndrome, type 2 diabetes and insulin resistance.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention belongs to the field of traditional Chinese medicine pain-relieving patches, and specifically discloses a preparation method and application of a self-heating product for dredging collaterals and relieving pain; this method uses a variety of Chinese herbal medicines including Erigeron breviscapus as raw materials, and obtains an extract for dredging collaterals and relieving pain through extraction and concentration processes, and then dilutes it and soaks non-woven fabric to make a medicinal paper layer. At the same time, a heat-generating layer is made by wrapping heat-generating materials such as iron powder and activated carbon with a film-coated non-woven fabric, and is fixed to the medicinal paper layer and the anti-adhesive layer by hot pressing to obtain a self-heating product. In addition, non-steroidal anti-inflammatory drugs such as ibuprofen can also be added to the extract for dredging collaterals and relieving pain to enhance the pain-relieving effect. During the preparation process, various process parameters such as extraction temperature and concentration pressure need to be strictly controlled to ensure product quality. After the product is prepared, it needs to be packaged in a sealed bag to isolate air to maintain its self-heating effect and medicinal efficacy. The present invention has the effects of dredging collaterals and relieving pain, and warming and soothing, and is suitable for relieving pain and discomfort caused by rheumatism, arthritis, etc.

Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor.The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

This specification describes softgel capsules comprising a filler material and a shell composition. The filler material may contain alkali metal salts of NSAIDs and acetaminophen, but may not contain povidone. The shell composition may contain a film-forming material. The softgel capsules may have at least about 99% assay stability at room temperature after 12 months.

The present invention provides a tegoprazan sugar acid salt and a preparation method therefor, the salt being pharmaceutically usable for gastroesophageal disease, gastroesophageal reflux disease, gastritis, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, non-erosive reflux disease (NERD) and the like. The tegoprazan sugar acid salt of the present invention has excellent water solubility and stability of tegoprazan, and thus can be particularly useful as a pharmaceutical injection preparation.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a system for delaying drug release of a water-soluble drug in hydrogel, and relates to the technical field of drugs, the system comprises a hydrogel, the interior of the hydrogel contains EGCG (epigallocatechin gallate), silver ions and NSAIDs (non-steroidal anti-inflammatory drug: diclofenac), and the hydrogel contains a water-soluble drug. The concentration range of the EGCG is 2-3%, the dosage of the EGCG is 0.2-0.3 g per 10 ml, the concentration range of the silver ions is 0.01-0.05%, the dosage of the silver ions is 0.001-0.005 g per 10 ml, the concentration range of the NSAIDs is 0.05-0.1%, the dosage of the NSAIDs is 0.005-0.0.01 g per 10 ml, a staged release mechanism of different drugs is adopted, the dosage of the EGCG is 0.2-0.3 g per 10 ml, the dosage of the silver ions is 0.01-0.05%, and the dosage of the NSAIDs is 0.05-0.1%. The sequential release of EGCG, silver ions and NSAIDs is realized by using the characteristics of concentration, molecular size, crosslinking, hydrophilicity and the like, and each component is ensured to act in the most effective time period.

The present application belongs to the field of pharmaceutical preparations, and particularly relates to a sustained-release analgesic pharmaceutical composition, a method for preparing same, and use thereof. The pharmaceutical composition of the present application comprises a drug, a delivery carrier, and a release regulator. The drug is selected from at least one of a local anesthetic and a non-steroidal anti-inflammatory drug. The release regulator is selected from a phospholipid compound. The delivery carrier is selected from a saccharide and an esterified form thereof. According to the present application, the coaction of the phospholipid compound and the delivery carrier can increase the plasma drug concentration upon the initial release in vivo, reduce the time to peak, enhance the analgesic effect in the early stage after a surgery, and ensure the long-term release of the drug, thus effectively relieving the postoperative pain, reducing the administration frequency, and promoting skin wound healing. The use of a specific solubilizer provides good stability for the drug and prevents precipitation. The composition can be administered through the wound, making it easy to use.

The present invention relates to a patch (1) for the topical treatment of sinusitis in a person to be treated, the patch (1) comprising at least one active section (2) with at least one active ingredient and at least one adhesive section (3), wherein the patch (1) is designed to be at least partially, preferably completely, occlusive in the at least one active section (2) and / or in the at least one adhesive section (3), wherein it is provided according to the invention that the at least one active section (2) contains a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives as the at least one active ingredient, and that the patch (1) has a shape that is adapted to the anatomical conditions of the application site, wherein the application site is in the face in the area of ​​at least one of the paranasal sinuses,preferably located in the area of ​​the cheek of the person to be treated, in order to enable targeted percutaneous treatment of the sinusitis.

The invention discloses an anti-prostatic cancer sulfonamide compound and application thereof, and belongs to the technical field of medicines. The structural formula of the sulfonamide compound is shown as a general formula (I), and the structure of the sulfonamide compound is different from that of traditional steroidal and non-steroidal androgen receptor antagonists. The compound has remarkable androgen receptor transcription inhibition activity, can be effectively combined with an androgen receptor ligand binding pocket in a competitive manner, blocks homologous dimerization of an androgen receptor, inhibits nuclear translocation of the androgen receptor, inhibits expression of downstream genes in an androgen receptor signal channel, and can be used for inhibiting the transcription of the androgen receptor. Further, the effects of antagonizing the transcriptional activity of an androgen receptor and inhibiting tumor cell proliferation are achieved; the compound can effectively inhibit the transcriptional activity of a mutant androgen receptor related to the clinical drug resistance of enzalutamide and the proliferation activity of drug-resistant cells, and shows better safety. The invention provides a new choice for prostatic cancer treatment and drug development.

Systems, methods, and computer programs disclosed herein relate to the determination of a dosage of a mineralocorticoid receptor antagonist (MRA) for a patient suffering from a disease that can be treated with an MRA.

The present invention relates to pharmaceutical compositions comprising etoricoxib and tramadol, or a pharmaceutically acceptable salt thereof, for the treatment of pain, which in addition to offering the possibility of an analgesic effect with a decrease in adverse events due to the reduction of the dose of one or both compounds, presents an improved stability, maintaining the dissolution and bioavailability of the composition to be administered; The composition manages to overcome the technological complexity that lies in having a drug with high sensitivity to light and humidity (tramadol), together with another fat-soluble drug with poor flow and excessive adhesiveness (etoricoxib), in a dispensing media in which their absorption is not affected through a water-free process, without affecting the release of both drugs.